RxDoctor Payments Data

Thomas Hunt, MD

Family Medicine · Eau Claire, WINPI 1013003060

Payments from drug & device makers

$3,989in general payments, 2019–2025

Across 257 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$707
  • Boehringer Ingelheim$480
  • Amgen$297
  • AstraZeneca$286
  • Lilly USA, LLC$276
  • plus $913 from 13 others

What the payments were for

  • Food & beverage$3,977100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,989 in reported general payments places this provider in the 90th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$2,009
Medicare patients
19
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide55$53,126
OzempicSemaglutide16$22,285
EliquisApixaban25$19,971
FarxigaDapagliflozin Propanediol22$12,386
JardianceEmpagliflozin15$10,722
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,567
JanuviaSitagliptin Phosphate11$6,518
Incruse ElliptaUmeclidinium Bromide15$5,349
Advair HfaFluticasone Propion/Salmeterol13$4,099
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$2,932
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm14$1,824
Metoprolol Succinate105$1,614
Albuterol Sulfate HfaAlbuterol Sulfate79$1,541
Tamsulosin Hcl70$1,241
Atorvastatin Calcium164$1,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$276$53,12655 claims
Novo NordiskOzempic$707$22,28516 claims
PfizerEliquis$98$19,97125 claims
GSKTrelegy Ellipta, Incruse Ellipta$38$13,91628 claims
AstraZenecaFarxiga$286$12,38622 claims
Boehringer IngelheimJardiance$480$10,72215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Eau Claire

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →